Am I alone here in reading between the lines that perhaps these may not be iminent
• progress with the development and commercialisation of the Group's existing product pipeline including the second generation eSensor(TM) instrument
• secure licensing agreements that will add assay content,and therefore revenues, for the Group's instrument platforms
• continue to explore selective acquisition opportunities which will strengthen and expand the Group's presence in the molecular diagnostics market
• negotiate licensing agreements and enter into strategic partnerships in non-healthcare markets, thereby leveraging the strength of the Group's instrument platforms, technology and intellectual property.
Has anyone else noticed how large each RNS is
It is interesting to note that the company seems to find it neccesary to keep repeating old info in every RNS - NOT NORMAL COMPANY PRACTICE
ie. ''NOISE'' to cloud what is really going on here
Sold out now for modest profit. May have judged this wrong but will be fascinating to see what happens over the next few months.
Osmetech stock quotes
Osmetech stock charts
Follow this thread
